Here are relevant reports on : cardiovascular-diseases-market
-
PEGylated Proteins Market by Consumables (PEGylation Kits, Reagents), Services, Protein Type (mAbs, Interferons), Application (Cancer Treatment, Chronic Kidney Diseases), End-User (Pharmaceutical & Biotechnology Companies)- Global Forecast to 2021
The global PEGylated proteins market size is projected to grow at a CAGR of 10.5%. The major drivers for the market include increase in R&D spending of pharmaceutical & biotechnology companies, growth in biologics sector, high prevalence of lifestyle disease, increasing focus on strategies to improve protein stability and circulating half-life. The rising opportunities in emerging markets and top-selling biologics drugs going off-patent in the near future will provide new growth opportunities for this market.
- Published: November 2016
- Price: $ 4950
- TOC Available:
-
Gastrointestinal Products Market | Gastroenterology Products Market by Devices (Endoscopy, Ablation system, Motility testing, Biopsy devices, Stenting devices, pH monitoring), Diseases (GERD), (IBD), Gastrointestinal cancer), End-User (Hospitals, ASC) - Global Forecast to 2029
The global gastrointestinal products market, valued at US$13.8 million in 2023, stood at US$14.7 million in 2024 and is projected to advance at a resilient CAGR of 6.1% from 2024 to 2029, culminating in a forecasted valuation of US$19.7 million by the end of the period. Market growth can be attributed to the growing prevalence of gastrointestinal diseases such as Crohn's disease, ulcerative colitis, irritable bowel syndrome (IBS), and colorectal cancer, which drives the demand for diagnostic and therapeutic products.
- Published: August 2024
- Price: $ 4950
- TOC Available:
-
Europe In Vitro Diagnostics Market by Product & Service (Kits, Instruments), Technology (Immunoassay, Hematology, Glucose Monitoring), Specimen (Blood), Site of Testing, Application (Endocrinology, Cardiology, Infectious Diseases) - Forecast to 2031
The Europe in vitro diagnostics market is expected to grow from USD 33.83 billion in 2026 to USD 49.49 billion by 2031, at a compound annual growth rate (CAGR) of 7.9% during the forecast period. The Key Players F. Hoffmann-La Roche Ltd (Switzerland), Abbott (US), Siemens Healthineers AG (Germany), Danaher Corporation (US), Thermo Fisher Scientific Inc. (US), bioMérieux (France), Sysmex Corporation (Japan), Becton, Dickinson and Company (US), Werfen (Spain), and Illumina, Inc. (US).
- Published: February 2026
- Price: $ 4950
- TOC Available:
-
US In Vitro Diagnostics Market by Product & Service (Kits, Instruments), Technology (Immunoassay, Hematology, Glucose Monitoring), Specimen (Blood), Site of Testing, Application (Endocrinology, Cardiology, Infectious Diseases) - Forecast to 2031
US In Vitro Diagnostics market, valued at US$37.43 billion in 2025, stood at US$40.15 billion in 2026 and is projected to advance at a resilient CAGR of 7.3% from 2025 to 2031, culminating in a forecasted valuation of US$57.18 billion by the end of the period. This growth is primarily driven by the rising prevalence of chronic and infectious diseases, the increasing demand for early and accurate diagnostic testing, the widespread adoption of advanced molecular diagnostic technologies, the growth in point-of-care testing, and continuous innovations in diagnostic instruments and assays.
- Published: December 2025
- Price: $ 4950
- TOC Available:
-
Vitamin D Therapy Market by Route of administration (Oral, Parenteral), Age Group (Children, Adult, Senior Adult), Purchase Pattern (OTC, Prescription), Application (Osteoporosis, Rickets, Autoimmune Disorder, Skin Diseases) - Global Forecast to 2024
The vitamin D therapy market is projected to reach USD 3.3 billion by 2024 from USD 1.9 billion in 2019, at a CAGR of 11.6% during the forecast period. Growth in this market is largely driven by the growing awareness about vitamin D deficiency and the presence of a large target patient population. On the other hand, the fortification of foods is likely to challenge the growth of this market. Some of the major players in this market include Abbott (US), Sanofi (France), GlaxoSmithKline plc (UK), Pfizer Inc. (US), Merck & Co., Inc. (US), Torrent Pharmaceuticals Ltd. (India), Novartis International AG (Switzerland), Alkem Laboratories (India), Sun Pharmaceutical Industries Ltd. (India), and Cadila Healthcare Ltd. (India).
- Published: April 2019
- Price: $ 4950
- TOC Available:
-
Esoteric Testing Market by Type (Endocrinology, Oncology, Neurology, Genetic Tests, Autoimmune, Infectious Diseases), Technology (ELISA, CLIA, Flow Cytometry, NGS, RT-PCR, Chromatography, Spectrometry), Specimen (Blood, Urine) - Global Forecast to 2029
The global esoteric testing market, valued at US$29.9 billion in 2023, stood at US$32.2 billion in 2024 and is projected to advance at a resilient CAGR of 8.5% from 2024 to 2029, culminating in a forecasted valuation of US$48.3 billion by the end of the period. Growth in the market is primarily driven by the growing geriatric population, advancements in esoteric tests for personalized medicine, increasing research funding for precision medicine, and increase in drug and alcohol abuse and stringent laws mandating drug and alcohol testing.
- Published: June 2024
- Price: $ 4950
- TOC Available:
-
Viral Vector & Plasmid DNA Manufacturing Market by Type (Viral Vector (Retroviruses, Adenoviruses, AAV, Lentiviruses), Plasmid DNA), Workflow (Upstream, Downstream), Application (Cell & Gene Therapy), Diseases (Cancer), End User - Global Forecast to 2028
The global viral vector manufacturing market, valued at US$4.8 billion in 2022, stood at US$5.5 billion in 2023 and is projected to advance at a resilient CAGR of 18.2% from 2023 to 2028, culminating in a forecasted valuation of US$12.8 billion by the end of the period. The growth of this market is majorly driven by g rising prevalence of target diseases and disorders, the availability of funding for gene therapy development, and effectiveness of viral vectors in gene therapy delivery.
- Published: June 2023
- Price: $ 4950
- TOC Available:
-
Carrier Screening Market by Product and Service, Type (Expanded (Customized, Predesigned) Targeted Diseases, Medical condition (Hematologic, Pulmonary), Technology (DNA Sequencing, PCR), End User, Region - Global Forecast to 2028
The global carrier screening market, valued at US$1.8 billion in 2022, stood at US$2.2 billion in 2023 and is projected to advance at a resilient CAGR of 19.7% from 2023 to 2028, culminating in a forecasted valuation of US$5.4 billion by the end of the period. The expansion of this market is majorly due to the development and availability of expanded carrier screening panels that cover a wide range of genetic conditions contribute to the market's growth.
- Published: January 2024
- Price: $ 4950
- TOC Available:
-
Sexually Transmitted Diseases Diagnostics Market by Disease Type (CT/NG, Gonorrhea, Syphilis, Genital Herpes, Hepatitis B, HIV/AIDS, HPV), End User (Laboratory, PoC) and Geography - Global Forecast to 2027
The STDs diagnostics market size is projected to reach $99,431.6 million by 2027 from $91,441.5 million in 2022, at a CAGR of 5.6% during the forecast period. Sexually transmitted diseases diagnostics market is driven by factors such as global prevalence of HIV, CT/NG, and other STDs and the growing awareness for early disease diagnosis, shift in focus from centralized laboratories to decentralized POC testing and rising technological advancements. On the other hand, an unfavorable reimbursement scenario is expected to limit market growth to a certain extent in the coming years.
- Published: January 2026
- Price: $ 4950
- TOC Available:
-
Urology Surgical Instruments Market by Product (Endoscopes, Endovision Systems, Peripheral Instruments, Consumables and Accessories), Application (Chronic Kidney Diseases, Benign Prostatic Hyperplasia, Oncology) - Global Forecast to 2021
The global urology surgical instruments market size is projected to grow at a CAGR of 8.2%. The growth of this market can be contributed to rising prevalence of kidney diseases and urinary tract infections; rising number of hospitals and growing hospital investments in surgical infrastructure; availability of investments, funds, and grants from government bodies; and rising geriatric population.
- Published: September 2016
- Price: $ 4950
- TOC Available:
Records 11 to 20 of 50
